Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Asos appoints Aaron Izzard as CFO

(Sharecast News) - Asos said on Tuesday that Aaron Izzard, currently director of group finance, has been appointed to the role of chief financial officer with effect from 1 July. Izzard succeeds Dave Murray, who will be stepping down as CFO to pursue other opportunities. He will remain with the company for a handover period to ensure a smooth transition, Asos said.

The online fashion retailer said the transition reflects its "evolution as it moves from a successful financial turnaround into a phase of sustained operational execution and long-term strategic growth".

It said Izzard brings more than two decades of experience across a range of senior finance roles in the retail and ecommerce industry. In his tenure at Asos, he has been "instrumental in driving a comprehensive cost-efficiency programme, demonstrating a relentless focus on operational improvements and improving customer experiences".

Asos said his leadership has supported the successful refinancing of the business and reshaped the group's approach to resource allocation, aligning financial investments more closely with strategic priorities.

Chief executive José Antonio Ramos Calamonte said: "Now is the time to further strengthen our focus on delivering sustainable, profitable growth and better customer experiences.

"Aaron has a strong track record of delivering operational efficiency and strategic thinking which will be key to continuing our successful transformation. I am confident that his experience and skills will be a great asset as CFO in the next phase of our journey."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.